Eisai Surprise Winner in MGI Auction

  
Generate a summary of this article
Listen to this article
Beta

Everyone knew that MGI Pharma was up for sale, but few expected mid-cap Japanese firm Eisai to emerge victorious. Eisai pushed its offer up to $41-per-share, all cash, even though there was only one other, non-definitive, offer on the table. The $3.3 billion deal nabs Eisai two records: the largest foreign acquisition by any Japanese pharma, and the year's largest specialty pharma purchase.

Everyone knew that MGI Pharma Inc. was up for sale, but few if any expected mid-cap Japanese pharma firm Eisai Co. Ltd. to emerge victorious last month from the formal auction run by Lehman Brothers. [See Deal] Eisai put up $3.3 billion, all cash—a healthy 39% premium to MGI’s closing share price the day before it announced it was seeking strategic alternatives, and about ten times MGI’s 2006 sales—and in doing so nabbed two records: the largest foreign acquisition by any Japanese pharma, and the year’s largest specialty pharma purchase.

Still, although Eisai was up against at least seven other interested parties, only one of these actually made an offer,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By Saba Afreen

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.